The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Successful Remission of Recurrent Anaphylaxis after Omalizumab Administration in a Patient with Systemic Mastocytosis

Omalizumab 투여로 호전된 반복적 아나필락시스를 보인 전신 비만세포증 1예

  • Moon, Hongran (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Jang, Hee Joon (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Lee, Choon Geun (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Kim, Young-Chan (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Yoo, Shin Hye (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Lee, Dong Soon (Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Kang, Hye-Ryun (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine)
  • 문홍란 (서울대학교 의과대학 서울대학교병원 내과) ;
  • 장희준 (서울대학교 의과대학 서울대학교병원 내과) ;
  • 이춘근 (서울대학교 의과대학 서울대학교병원 내과) ;
  • 김영찬 (서울대학교 의과대학 서울대학교병원 내과) ;
  • 유신혜 (서울대학교 의과대학 서울대학교병원 내과) ;
  • 이동순 (서울대학교 의과대학 서울대학교병원 진단검사의학과) ;
  • 강혜련 (서울대학교 의과대학 서울대학교병원 내과)
  • Received : 2017.05.07
  • Accepted : 2017.08.08
  • Published : 2018.02.01
⟨ Previous Next ⟩

Abstract

Mastocytosis is a disorder characterized by abnormal mast cell proliferation and accumulation in one or more tissues. It presents in two major variants: cutaneous mastocytosis and systemic mastocytosis. Because the symptoms are related to mast cells, histamine receptor antagonists and leukotriene receptor antagonists are recommended as therapeutic options. Here, we report a 54-year-old male patient with a history of urticaria pigmentosa who presented with recurrent anaphylaxis. His serum tryptase level was 31.7 ng/mL and mast cell infiltration was observed in his bone marrow. He had frequent attacks of anaphylaxis despite treatment with ketotifen, levocetirizine, and montelukast. Symptoms related to systemic mastocytosis were controlled and the patient exhibited no recurrence of anaphylaxis following the introduction of monthly omalizumab injection. Omalizumab can be considered as a treatment option in patients with systemic mastocytosis unresponsive to conventional oral medications.

저자들은 빈번한 아나필락시스를 보이는 환자에서 비활동성 비만세포증을 확진하였으며, omalizumab으로 효과적으로 치료하였기에 문헌고찰과 함께 보고하는 바이다.

Keywords

References

  1. Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009;123:680-686. https://doi.org/10.1016/j.jaci.2008.11.018
  2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-2405. https://doi.org/10.1182/blood-2016-03-643544
  3. Bonadonna P, Zanotti R, Muller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010;10:347-353. https://doi.org/10.1097/ACI.0b013e32833b280c
  4. Bae MH, Kim HK, Park CJ, et al. A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation. Ann Lab Med 2013;33:125-129. https://doi.org/10.3343/alm.2013.33.2.125
  5. Huh EJ, Park SY, Choi SR, et al. Aggressive systemic mastocytosis following ovarian germ cell tumor. Korean J Hematol 2005;40:129-133. https://doi.org/10.5045/kjh.2005.40.2.129
  6. Park MN, Kim GA, Chey MG, Shim GH. A case of diffuse cutaneous mastocytosis in a newborn. Korean J Perinatol 2014;25:105-109. https://doi.org/10.14734/kjp.2014.25.2.105
  7. Pardanani A. Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 2016;91:1146-1159. https://doi.org/10.1002/ajh.24553
  8. Valent P. Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res 2013;3:159-172.
  9. Spector MS, Iossifov I, Kritharis A, et al. Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor beta chain and KIT V654A. Leukemia 2012;26:1422-1425. https://doi.org/10.1038/leu.2011.354
  10. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-453. https://doi.org/10.1111/j.1365-2362.2007.01807.x
  11. Zanotti R, Lombardo C, Passalacqua G, et al. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol 2015;136:135-139. https://doi.org/10.1016/j.jaci.2014.11.035
  12. Arredondo AR, Gotlib J, Shier L, et al. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol 2010;85:600-606. https://doi.org/10.1002/ajh.21713
  13. Bell MC, Jackson DJ. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol 2012;108:383-384. https://doi.org/10.1016/j.anai.2012.02.021
  14. Cardet JC, Akin C, Lee MJ. Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother 2013;14:2033-2045. https://doi.org/10.1517/14656566.2013.824424